Introduction
Neurodevelopmental disorders including Rett's syndrome (RS), Rett-like syndromes, and Angelman's syndrome (AS) present with severely restricted or absent expressive language, seizures, and stereotypies and are characterized by vast genetic heterogeneity and significant clinical overlap. 1 and others; these probably account for a fraction of previously unexplained underlying genetic etiology.
2-7 Achieving a clinical diagnosis in this heterogeneous group of disorders, which can be of a very diverse genetic background, is therefore highly challenging. Loss-of-function mutations in the MEF2C gene have been found in patients with a complex, RS-like phenotype.
2,8-10
The MEF2C gene was originally identified as the phenocritical gene in the 5q14.3 microdeletion syndrome. 9, 11, 12 Consequently, patients with intragenic deletions and point mutations were identified, further confirming the pathogenicity of haploinsufficiency of the MEF2C gene. 13, 14 Haploinsufficiency of MEF2C has been suggested as the most likely pathogenic mechanism as patients with both deletions and truncating and missense MEF2C mutations present with a similar, distinct phenotype. On the other hand, there are only a few reports of duplications of the MEF2C gene. These individuals seem to present with a milder phenotype of mild cognitive impairment, speech disorder, microcephaly, and mild ventriculomegaly. 9, 15 Furthermore, a case of an affected monochorionic twin pregnancy with MEF2C duplication and abnormal corpus callosum in both twins has been described, and a pathogenic role for MEF2C overexpression in the developing brain has been proposed as the causative mechanism in MEF2C duplication.
15
Typical clinical characteristics in individuals with MEF2C mutations encompass severe global developmental delay with absent speech, limited walking, seizures, and stereotypic movements. Pregnancy and neonatal course are typically uneventful, but early hypotonia, feeding difficulties, and poor eye contact can occur. Some but not all of the MEF2C patients show stereotypic behavior, particularly hand flapping, clapping, mouthing, head rocking, and hand biting. 10, 13, 14 Purposeful hand use is generally present and retained. Patients can have various types of epilepsy, although they can also be seizure-free. Seizures arise typically during infancy or early childhood and are commonly associated with fever. Most of the time, the seizures respond well to medication. Growth is generally normal, and there is no known increased risk of internal congenital malformations. In contrast to patients with RS, no period of developmental regression or microcephaly is observed. Furthermore, commonly reported symptoms are episodic hyperventilation, autistic features, tendency to recurrent infections (upper respiratory tract), constipation, and ametropia (myopia, hyperopia, strabismus). 10 Minor brain abnormalities have been described with delayed myelination reported in point mutation cases and cortical malformations in patients with microdeletions.
13
One case of concentric myocardial hypertrophy has been described in a patient with a MEF2C deletion, 16 but this has not been subsequently confirmed as an associated feature in other studies and may be a coincidental finding. The phenotypic overlap with RS was noted and a common molecular pathway was proposed. MEF2C loss-of-function mutations diminish synergistic transactivation of both MECP2 and CDKL5.
17 MEF2C codes for a transcription factor essential for normal brain, craniofacial, heart, and vascular development.
17-19
We present a new cohort of patients with MEF2C mutations, one whole gene, four partial gene deletions, and a new point mutation. We compare our findings with those of disorders with significant phenotypic overlap and discuss the MEF2C distinguishing features.
Methods
We present comprehensive clinical data of six novel patients presenting with MEF2C-associated syndrome. Aberrations in the MEF2C gene were found using OGT (Oxford Gene Technology) chromosomal microarray in patients 1, 2, and 4, using the SNP6.0 array in patient 3, and using multiplex ligation-dependent probe amplification in patient 6. In patient 5, a nonsense mutation in MEF2C was found by next generation sequencing on a severe infantile epilepsy gene panel, and the variant was confirmed with Sanger sequencing of the MEF2C exon 3.
We reviewed the literature of published MEF2C cases and compared our findings to further delineate the MEF2C clinical presentation.
13,14
We compared the findings in our cohort of MEF2C patients with other severe neurodevelopmental disorders presenting with seizures, severely restricted or absent expressive language, gait difficulties, and stereotypic behavior. We reviewed the literature to include a comprehensive clinical presentation of Rett's, Angelman's, PittHopkins', Mowat-Wilson's, Christianson's, Phelan-McDermid's syndromes, adenylosuccinase deficiency, and mutations in the genes FOXG1, CDKL5, IQSEC2, STXBP1, CNTNAP2, and WDR45.
4,5,20-28

Results
Clinical Features of Our Cohort and of Other Patients with the MEF2C-Linked Syndrome
Clinical features of the six patients (five females and one male) with a de novo pathogenic MEF2C mutation are presented (►Table 1). The oldest patient in our cohort was 10 years and 7 months old at her last examination, and the oldest reported in the literature was 14 years old.
13,14
All patients manifested delay in gross motor development, with latest age for sitting unaided by 18 months, crawling by 5 years, and pulling to stand by 7 years. Patient 1 that showed most severe delay in achieving major motor milestones was the one with the largest (5.6 Mb) deletion encompassing multiple genes. Expressive language in MEF2C syndrome is typically severely impaired or absent. Only two of our patients (patient 3 and 6) developed some limited speech and communication abilities. While patient 3 had no words by the age of 40 months, she showed significant improvement later on and was using a few words in context by the age of 9 years. Patient 6 displayed good understanding and was using up to maximum 15 words by the age of 3 years.
Magnetic resonance imaging of the brain was performed in five of our patients and showed mild central nervous system abnormalities in four (80%), including frontal cortical atrophy and moderate ventriculomegaly, abnormalities of corpus callosum, and posterior white matter abnormalities. 
Ceiling gazing þ n/a n/a n/a n/a n/a Facial features of patients 1, 3, and 5 are presented in ►Fig. 1. Patients are not overtly dysmorphic, but do present with distinct minor facial characteristics including a high and wide forehead, flat nasal bridge, epicanthic folds, tented upper lip, down turned corners of the mouth, short columella, a short philtrum with prominent pillars, and often pale blue eyes. Our patient with cleft palate (CP) is the first MEF2C patient presenting with abnormalities of craniofacial development.
None of our patients displayed the fossa abnormality (pit/ sternal fistula), which was previously reported as a specific recurrent clinical finding in MEF2C patients.
12,14,29,36 None of our patients had developed any life-threatening symptoms.
Genetic Features of Our Cohort
Distinct deletions of MEF2C in patients 1, 2, and 4 are presented on chromosomal microarray image (►Fig. 2). The MEF2C c.220G>T mutation found in patient 5 results in a premature stop codon at the protein level (pGlu74Ter) and is therefore predicted to be pathogenic. This mutation has not been previously reported. It is located in the Mef2 DNA (deoxyribonucleic acid) binding domain of the MEF2C transcription factor and is predicted to be pathogenic according to MutationTaster (MT; www.mutationtaster.org).
Clinical Comparison with Other Severe Neurodevelopmental Disorders with Seizures, Absent Speech, and Stereotypic Hand Movements
An overview is presented (►Table 2). The phenotypic overlap to RS and other similar syndromes is significant, but with the important distinction that in MEF2C, usually there is no microcephaly and no neurodevelopmental regression. There are some possible unique distinguishing features such as "ceiling-gazing" stereotypy.
We think that the subtle facial phenotype, as described previously, the "ceiling-gazing" behavior, and the presence of hemangiomas could be a clue to a MEF2C diagnosis.
Discussion
Clinical Delineation of "MEF2C Syndrome"
Patients with MEF2C syndrome show severe to profound developmental delay, limited or absent speech, seizures, hypotonia, limited walking abilities, and characteristic stereotypic behavior. Frequent findings also include poor eye contact, autistic behavior, episodic breathing abnormalities, feeding difficulties, constipation, strabismus, sleeping problems, a tendency to frequent infections, and subtle facial dysmorphism. The presenting clinical phenotype, although not instantly recognizable, is characteristic for MEF2C syndrome and compatible with that previously described in MEF2C clinical picture. 13, 14 In all of our patients, the diagnosis was suspected clinically based on their array of distinctive features. In most cases, there was preliminary exclusion of RS or AS. MEF2C is a transcription factor important in multiple developmental processes including neurogenesis and synaptic formation, myogenesis, development of the anterior heart field, neural crest, craniofacial development, chondrocyte hypertrophy and vascularization, endothelial cell proliferation, and lymphoid development. 10, 30, 31 In the developing brain, it regulates excitatory synapse number, dendrite morphogenesis, and differentiation of postsynaptic structures. It is highly expressed in frontal cortex, entorhinal cortex, cerebellum, dentate gyrus, and amygdala. 12 These findings explain the underlying molecular substrate for global developmental delay, seizures, hypotonia, autistic features, and presence of minor, usually nonspecific, brain abnormalities. Interestingly, periventricular heterotopia has been described in patients with 5q14.3q15 microdeletion, 32 but this has not been subsequently confirmed and it is thought to be due to other genes included in the deletion of the patients described by Cardoso et al.
32
Dermatological abnormalities were frequently described as part of the 5q14.3 microdeletion syndrome. This has been explained by the contiguous gene deletion involving the adjacent RASA1 gene, haploinsufficiency of which is causative for capillary malformation-arteriovenous malformation syndrome. 33 We confirm this association in our patient (number 1) presenting with multiple skin hemangiomas and a multiple gene deletion encompassing the RASA1 gene. Furthermore, we report on a patient (number 2) with a large capillary nevus of the lower limb but with an intragenic MEF2C deletion, encompassing the first three exons of MEF2C gene but not the RASA1 gene. As MEF2C has been shown to play an important role in vessel development targeting both genes for endothelial cell organization as well as smooth muscle cell differentiation, this might explain the cause of the capillary malformation in our patient, hereby expanding the MEF2C clinical phenotype.
34
The association might also be due to a long-range effect of the deletion on RASA1. The intragenic deletion in our patient with capillary malformation results in the deletion of exons 1 to 3, which are the same exons as were previously reported by Tanteles et al as being deleted in a Cypriot patient who also presented with a cutaneous vascular malformation. 14 We are hereby proposing an association of MEF2C exon 1 to 3 deletion with vascular malformations and a new genotype-phenotype correlation. Furthermore, MEF2C is an important regulator of cardiac myogenesis and is expressed in heart cells before the formation of the heart tube. In homozygous mice for a MEF2C null mutation, the heart tube does not correctly loop, the right ventricle does not form, and a subset of cardiac muscle genes are not expressed.
19 So far, cardiomyopathy has only been reported in one patient. 16 Ultrasound heart examinations performed in our cohort showed normal scans except for patient 2. This patient was born with a persistent foramen ovale and a patent ductus arteriosus, which was closed with a coil; however, in that particular case, the mother has been treated with valproate during pregnancy, and this may have contributed to the offspring's cardiac presentation.
Our cohort includes a patient with a MEF2C point mutation, leading to a premature stop codon at the 74th amino acid of the MEF2C protein, and a CP. Family and prenatal history were not contributory for clefting. CP is quite frequent in the general population with an estimated incidence of 1 in 2,000. On the other hand, mice lacking MEF2C function manifest CP, and MEF2C has been proven to participate in craniofacial development.
30 Duplications of MEF2C have been associated with cranial asymmetry and metopic prominence in humans. 35 Further patient descriptions would be necessary to investigate whether CP may be an additional feature of this syndrome. A jugular fossa abnormality (a jugular pit or fistula), which was previously presented as a characteristic recurrent clinical sign of MEF2C patients and a possible clue to the MEF2C diagnosis, 12, 14, 29, 36 was not present in our cohort of patients.
In patients with RASA1 deletion, screening for associated vascular malformations is indicated (brain and spine imaging). In view of hereby published findings, further surveillance might also focus on craniofacial abnormalities (CP) and congenital heart disease. Melatonin has been reported as helpful in ameliorating sleep disturbances. Impaired vision, including myopia, hypermetropia, and astigmatism, seem to be common, and ophthalmological evaluation would be warranted to improve the outcome.
Genotype-Phenotype Correlation and Variability
All of the reported variants in the MEF2C gene occurred de novo and were heterozygous. Clinical variability may be partially explained by the type of mutation, and partial MEF2C deletions have been reported to cause a milder phenotype and have a better prognosis.
14 Patients with small deletions and intragenic mutations were more likely to acquire walking skills. 10 Some patients never experience seizures, especially patients with partial MEF2C deletions. 12,13,37 A lower risk of refractory seizures has been described for patients with point mutations.
10
To the best of our knowledge, only 10 patients with MEF2C point mutations including our patient have been identified so far, 13 and this limits the study of possible genotypephenotype correlations. Still, some characteristics seem to emerge. All of our patients with smaller intragenic deletions did achieve independent walking (youngest at the age of 2 years, oldest at the age of 3 years). Smaller intragenic deletions therefore show a less severe effect as would also be expected, whereas the majority of 5q14.3-q15 microdeletion syndromes do not walk and remain very hypotonic.
9
Half of point mutation patients reported by Rocha et al have achieved independent ambulation, a finding previously reported by Novara in a review of 10 patients where only one patient (with a point mutation) reached independent walking (at the age of 3 years). Our patient with a point mutation was only 3 years and 1 month old at the time of her last examination; therefore, we cannot confirm the suggested lesser effect of the intragenic point mutation compared with a deletion regarding the ambulation skills.
Although lack of speech is considered a diagnostic finding in MEF2C, we report on two patients with intragenic deletions who developed limited speech abilities (one with a maximum word vocabulary of 15 words and good understanding at the age of 3 years, and the other using a few words in context at the age of 9 years). Besides our two patients, there is only one other case reported that maintained speech. 37 All these three patients harbor intragenic MEF2C deletions: one patient displays a deletion of exons 2 to 10 (patient 3, this study) and, interestingly, both two other patients display the same deletion of exons 1 to 2 (patient 6, this study, and a patient with 10 consistent words plus jargon as reported by Paciorkowski et al).
14,37
Distinguishing Distinction of these syndromes through clinical phenotyping is important for better diagnostic clarity and provision of better prognostic information. Lumping them under nonspecific umbrella terms such as Rett-like and Angelmanlike has been discouraged, as there is gathering phenotypic and clinical history data to recognize most of these disorders as separate diagnostic entities.
38,39
Distinguishing features are quite a few; the first worth consideration is acquired microcephaly, which is present in many of these disorders (Rett, Angelman, CDKL5, SLC9A6, and TCF4). However, postnatal deceleration in head growth has been eliminated from the necessary criteria for RS, as it was not present in all patients. 40 
n/a n/a n/a Emaciation, long narrow face with prominent nose, jaw and ears Cerebellar, brainstem and hippocampus atrophy, CC hypoplasia
Normal / "frontal high-amplitude 2-3 Hz" spike and wave activity (Continued) Abbreviations: -, absence of feature; þ, presence of feature; ASD, autism spectrum disorder; CC, corpus callosum; CSF, cerebrospinal fluid; F, female; GERD, gastroesophageal reflux disease; GP, globus pallidus; HR, heart rate; M, male; n/a, data not available; PDA, patent ductus arteriosus; SN, substantia nigra; VSD, ventriculum septum defect.
progressive loss of previously acquired skills neither a previous period of normal development. 18 Phenotypic overlap between MEF2C and Rett has been explained by a shared molecular pathway, and decreased expression of MECP2 and CDKL5 (but not TCF4) was measured in vivo in blood of patients with a MEF2C proven mutation.
17
In some congenital and infantile forms of RS, CDKL5 and FOXG1 mutations were found as causative. CDKL5 gene mutations have been variably associated with early infantile epileptic encephalopathy, X-linked dominant infantile spasm syndrome, the early onset seizure variant of Rett syndrome and other epileptic disorders such as West syndrome. 39 In most cases, patients present with a distinct clinical profile that in majority does not fulfill the Rett criteria. FOXG1 patients usually present with congenital microcephaly or early onset deceleration of head growth resulting in microcephaly before 4 months of age. Presentation in point mutations cases is usually severe and excludes the typical Rett regression period after a period of normal development, whereas 14q12 deletions are characterized by a normal perinatal period followed by a phase of regression at the age of 3 to 6 months. 4 FOXG1 presentation can include abnormalities of craniofacial development (CP). Genes identified as causative in early epileptic encephalopathies and disorders of neurodegeneration with brain iron accumulation (NBIA) have been shown to present with a broad phenotypic spectrum and also include a Rettlike phenotype. 39, 42, 43 Striking clinical similarities between the X-linked neurodegeneration disorder BPAN ("β-propeller protein-associated neurodegeneration," an NBIA caused by mutations in the gene WDR45) and RS were described, and the causative WDR45 gene was suggested to be included in the multigene panels when testing for an RS or a variant RS.
44
Interestingly, both Rett and BPAN show X-linked dominant inheritance. In the case of BPAN, somatic mosaicism was suggested as an explanation for extreme phenotypic variability in males who can present with severe neonatal encephalopathy or mild intellectual disability based on the timing of mutation acquisition during embryogenesis.
Biallelic mutations in CNTNAP2 have been found to cause an autosomal recessive intellectual disability syndrome with epilepsy and cortical dysplasia. Phenotypic spectrum of CNTNAP2 seems to be broad involving behavioral anomalies, hand wringing, and abnormal breathing patterns, and therefore clinical presentation can be rather difficult to distinguish from other disorders that present with early onset seizures, developmental regression, and lack of or very limited speech. 6 In several CNTNAP2 patients, speech development was reported as normal and the microcephaly is rare; specific distinguishing features are cortical dysplasia and decreased deep tendon reflexes, but the cortical dysplasia does not seem to be as frequent as previously thought.
6
As we have shown, the etiology of syndromes presenting with severe intellectual disability, epilepsy, absence of speech, stereotypic movements, hypotonia, and limited walking ability is heterogeneous, including genes associated with epileptic encephalopathies, intellectual disability, autism spectrum disorder, and NBIA disorders. First-tier testing through array comparative genomic hybridization is important as the majority (48/58) of the deleterious alleles affecting MEF2C so far were pathogenic copy number variants. Next, exome or broad panel sequencing, including the aforementioned genes, would be indicated, as the genes mentioned participate in various cellular pathways and are currently included in different genetic sequencing panels (intellectual disability, epileptic encephalopathy, clinical epilepsy panels, NBIA disorders).
Establishing the genetic diagnosis in a patient with a MEF2C-associated syndrome is important for better understanding of the natural history of this disorder, focusing attention on relevant health issues, prognostic consideration, and also avoidance of unnecessary testing. Understanding of underlying molecular mechanisms and shared pathways of these neurodevelopmental disorders (MEF2C, MECP2, CDKL5) is important for planning pharmaceutical trials for possible future targeted treatment of the associated neurobehavioral symptoms. Although new cases are emerging, MEF2C-associated syndrome is relatively new and therefore its natural history has not yet been fully studied. Several of the symptoms are age-dependent, and several of the reported patients were too young to present the possible clinical manifestations. Therefore, further studies will be essential to more fully delineate the MEF2C clinical phenotype.
